Trials / Completed
CompletedNCT03615443
Noninvasive vs. Invasive Lung Evaluation
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 306 (actual)
- Sponsor
- Guardant Health, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Tumor derived cell free DNA (cfDNA) is increasingly used in the clinic to obtain genotype information about lung cancer, but its concordance with concurrent tumor-derived sequenced data is not known. The purpose of the trial is to determine the non-inferiority of cfDNA-based vs. tumor tissue-based genotyping as it pertains to the detection of National Comprehensive Cancer Network (NCCN)-recommended biomarkers in first line, treatment naive, non-squamous Non-Small Cell Lung Cancer (NSCLC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Guardant360 | Guardant360 is a comprehensive, non-invasive tumor sequencing test. |
Timeline
- Start date
- 2016-02-12
- Primary completion
- 2020-11-23
- Completion
- 2020-11-23
- First posted
- 2018-08-03
- Last updated
- 2021-05-03
Source: ClinicalTrials.gov record NCT03615443. Inclusion in this directory is not an endorsement.